🤝 En la Comida con el Experto de Roche en el #LVIIICNN25, los Dres. José Luis Herrera Acevedo y Mario Eduardo Alamilla compartieron perspectivas sobre la nefritis lúpica, sus desafíos y nuevas estrategias terapéuticas. 🩺✨

Dual BLyS/APRIL inhibition in LN Telitacicept vs Standard therapy ▫️CRR: 29.55 vs 11.36%, P= .034 ▫️PERR: 68.18 vs 45.45%, P= .031 ▫️UPCR ↓: 0.97 g/g (63.82%) vs 0.31 g/g (25.31%) Telitacicept: more prominent therapeutic effect in type V LN and those with proteinuria ≥3 g/d

The KDIGO 2025 IgAN guideline now encourages a more liberal kidney biopsy policy and suggests aiming for stricter proteinuria control, with a goal of <0.5 g/d, ideally <0.3 g/d, and a stable estimated glomerular filtration rate. 🔗kidney-international.org/article/S0085-…

Anti-GBM disease ▫️PEX: essential treatment together CYC + glucocorticoids ▫️Immunoadsorption is emerging as an alternative ▫️RTX: alternative for those with contraindications to CYC or in refractory disease ▫️Imlifidase: promise for rapid clearance of circulating and tissue

Rituximab as Adjunctive Therapy in FSGS ▫️Response rates: 3, 6, and 12 months: 57, 71, and 74% ▫️12 month RTX response was positively associated: -↓ Proteinuria: OR= 0.49, P = 0.043 -Steroid dependency: OR = 20.59, P = 0.002 ▫️Sustained remission in 1year responders: 69.4%

Un placer tenerte Maria Jose Soler como ponente invitada y que hayas compartido con todos los residentes del NefrologíaHGM, sin duda fue una gran sesión llena de aprendizaje.

Les comparto nuestra más reciente publicación en colaboración con un gran equipo de nefrólogos 🇨🇱 🇲🇽 🇪🇸 “Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis” 🔗 lupus.bmj.com/content/12/2/e…

Un placer haber contado con la participación de grandes ponentes internacionales en el “Módulo de Onconefrología” del NefrologíaHGM, donde sin duda, todas sus aportaciones fueron de gran provecho para nuestros médicos residentes. Maria Jose Soler, Marco Bonilla, Quim Casals

Urinary sediment predicts active proliferative glomerular diseases In predicting: ▫️AUC RBC: 0.86 and WBC: 0.83 ▫️AUC RBC + WBC: 0.88 ▫️AUC RBC+WBC+RTEC+RBC casts: 0.90 ▫️AUC gender+age+serum creatinine + urine proteins: 0.8 ▫️AUC all these variables: 0.96

Great news: in the APPLAUSE trial, iptacopan slows eGFR decline in people with IgA nephropathy. novartis.com/news/media-rel…

IgAN Active IgAN ▫️Sustained proteinuria ▫️Persistent haematuria ▫️Rapidly declining eGFR ▫️Histological: M1, E1, C1/C2, Interstitial inflammation Chronic fibrotic IgAN ▫️Clinical proteinuria ▫️Minimal/no haematuria ▫️Slowly declining eGFR ▫️Histological:T1/T2

Jornadas Médicas Interdisciplinarias Hospital General Síndrome Neuro-Cardio-Reno-Metabólico

Excelente grupo de profesores representando a Nefrología en las jornadas médicas multidisciplinarias Hospital General Pablo Galindo Juan C. Díaz 🫘 Daniel Díaz - García

From Evidence to Action: DKD ▫️Early detection of albuminuria ▫️Triple therapy: RASi + SGLT2i + nsMRA can delay kidney failure by up to 10 years ▫️Proposal "3-in-3": 3 therapies within the first 3 months after diagnosis ▫️New interventions must be integrated: ra-GLP

Clausura de la 1era Generación del Fellowship de Enfermedades Glomerulares GlomCon Iberolatinoamérica GlomCon Ibero-LatinoAmérica ! Muchas felicidades a todos, un gusto formar parte de los instructores del grupo Depósitos!

IgA nephropathy ▫️The traditional stepwise treatment model, where therapies are added sequentially depending on the clinical response, may soon be replaced by a more aggressive, simultaneous approach ▫️This approach targets both the CKD elements and the immunological factors

Finerenone + SGLT2i in IgA nephropathy Retrospective study: 76 patients with IgAN UPCR ▫️Finerenone + SGLT2i: -3 month: 40.89% -6 month: 54.62% ▫️Finerenone: -3 month: 23.72% -6 month: 30.88% ▫️SGLT2i: -3 month: 24.69% -6 month: 24.69% All p< 0.05

Atención a todos los interesados. Gran oportunidad de formar parte de una excelente sede formativa de nefrólog@s👇

A pocos días, de la segunda edición del Curso de Onconefrología. Sede InCan y online. 🦀🫘 Inscripción 👇 shre.ink/So1J

Prognostic relevance of persistent haematuria in lupus nephritis ▫️178 patients ▫️77.5%: initial haematuria ▫️37.1%:persistent haematuria ▫️Persistent haematuria: ↑ SLEDAI ↓ Hemoglobin and Albumin ↓ C3 and C4 ↑ BUN and sCr ↑ Mortality ↑ Renal replacement therapy